1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

In development [GID-TA11485] Expected publication date: 20 August 2025

  • Project information
  • Project documents

NIHRIO BN: 37640-Zanubrutinib-for-Mantle-Cell-Lymphoma-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)